RT Journal Article
T1 Lymph Node Dissection in Patients With Melanoma and Sentinel Lymph Node Metastasis: An Updated, Evidence-Based Decision Algorithm.
T2 Disección ganglionar en el paciente con melanoma y metástasis en el ganglio centinela: propuesta de decisión basada en la evidencia actual.
A1 Moreno-Ramírez, D
A1 Boada, A
A1 Ferrándiz, L
A1 Samaniego, E
A1 Carretero, G
A1 Nagore, E
A1 Redondo, P
A1 Ortiz-Romero, P
A1 Malvehy, J
A1 Botella-Estrada, R
A1 miembros del Grupo Español de Dermato-Oncología y Cirugía. Academia Española de Dermatología y Venereología, 
K1 Adjuvant therapy
K1 Biopsia selectiva del ganglio centinela
K1 Disección ganglionar
K1 Lymph node dissection
K1 Melanoma
K1 Sentinel lymph node biopsy
K1 Tratamiento adyuvante
AB Recent publication of the results of clinical trials in which lymph node dissection was not associated with any survival benefit in patients with sentinel node metastasis makes it necessary to reconsider the treatment of patients with melanoma. This article provides an update on the available evidence on the diverse factors (routes of metastatic spread, predictors, adjuvant therapy, etc.) that must be considered when treating patients with sentinel node-positive melanoma. The authors propose a decision-making algorithm for use in this clinical setting. The current evidence no longer supports lymph node dissection in patients with low-risk sentinel node metastasis (sentinel node tumor load ≤1mm).
YR 2018
FD 2018-04-09
LK https://hdl.handle.net/10668/24821
UL https://hdl.handle.net/10668/24821
LA en
LA es
DS RISalud
RD Apr 17, 2025